Revolution Medicines, Inc. (RVMD)
176.35
-4.35
(-2.41%)
USD |
NASDAQ |
Nov 12, 16:00
176.07
-0.28
(-0.16%)
After-Hours: 06:50
Revolution Medicines Enterprise Value : 35.70B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 35.70B |
| November 11, 2026 | 36.64B |
| November 10, 2026 | 39.31B |
| November 09, 2026 | 40.84B |
| November 06, 2026 | 39.14B |
| November 05, 2026 | 35.98B |
| November 04, 2026 | 40.75B |
| November 03, 2026 | 39.56B |
| November 02, 2026 | 38.25B |
| October 30, 2026 | 38.93B |
| October 29, 2026 | 38.71B |
| October 28, 2026 | 38.37B |
| October 27, 2026 | 37.83B |
| October 26, 2026 | 37.33B |
| October 23, 2026 | 38.00B |
| October 22, 2026 | 38.15B |
| October 21, 2026 | 39.57B |
| October 20, 2026 | 40.06B |
| October 19, 2026 | 36.95B |
| October 16, 2026 | 36.04B |
| October 15, 2026 | 38.49B |
| October 14, 2026 | 39.41B |
| October 13, 2026 | 38.31B |
| October 12, 2026 | 39.50B |
| October 09, 2026 | 38.60B |
| Date | Value |
|---|---|
| October 08, 2026 | 38.24B |
| October 07, 2026 | 41.00B |
| October 06, 2026 | 40.78B |
| October 05, 2026 | 42.47B |
| October 02, 2026 | 42.25B |
| October 01, 2026 | 42.08B |
| September 30, 2026 | 41.95B |
| September 29, 2026 | 41.06B |
| September 28, 2026 | 40.47B |
| September 25, 2026 | 41.17B |
| September 24, 2026 | 40.07B |
| September 23, 2026 | 38.12B |
| September 22, 2026 | 38.57B |
| September 21, 2026 | 38.55B |
| September 18, 2026 | 38.16B |
| September 17, 2026 | 39.45B |
| September 16, 2026 | 39.23B |
| September 15, 2026 | 41.14B |
| September 14, 2026 | 41.20B |
| September 11, 2026 | 40.91B |
| September 10, 2026 | 40.82B |
| September 09, 2026 | 41.75B |
| September 08, 2026 | 41.67B |
| September 04, 2026 | 42.25B |
| September 03, 2026 | 42.43B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 92.52B |
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Oncolytics Biotech, Inc. | 42.70M |
| Intellia Therapeutics, Inc. | 1.236B |
| Twist Bioscience Corp. | 7.085B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -407.46M |
| Revenue (Quarterly) | 197.56M |
| Total Expenses (Quarterly) | 605.02M |
| EPS Diluted (Quarterly) | -1.896 |
| Gross Profit Margin (Quarterly) | 97.26% |
| Profit Margin (Quarterly) | -206.2% |
| Earnings Yield | -5.16% |
| Normalized Earnings Yield | -4.742 |